BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization

Cancer Science

Volumn 101, Issue 8, 2010, Pages 1813-1821

  Shigeta, Junichi ^a   Katayama, Kazuhiro ^a   Mitsuhashi, Junko ^a   Noguchi, Kohji ^a   Sugimoto, Yoshikazu ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; COMPLEMENTARY DNA; DIMER; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; CANCER RESISTANCE; COVALENT DIMERIZATION; DIMERIZATION; GENETIC TRANSFECTION; GROWTH INHIBITION; IMMUNOFLUORESCENCE MICROSCOPY; MOLECULAR CLONING; MUTANT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; DRUG RESISTANCE, NEOPLASM; INDOLES; MICE; MITOXANTRONE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN MULTIMERIZATION; TRANSFECTION;

EID: 77954851709     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01605.x     Document Type: Article

References (45)

1. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet 1995, 29:607-49.
2. Chen CJ, Chin JE, Ueda K. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47:381-9.
3. Ueda K, Clark DP, Chen CJ, Roninson IB, Gottesman MM, Pastan I. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem 1987, 262:505-8.
4. Pastan I, Gottesman MM, Ueda K, Lovelace E, Rutherford AV, Willingham MC. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 1988, 85:4486-90.
5. Cole SP, Bhardwaj G, Gerlach JH. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258:1650-4.
6. Doyle LA, Yang W, Abruzzo LV. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998, 95:15665-70.
7. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999, 59:4237-41.
8. Ross DD, Yang W, Abruzzo LV. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999, 91:429-33.
9. Maliepaard M, van Gastelen MA, de Jong LA. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999, 59:4559-63.
10. Litman T, Brangi M, Hudson E. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000, 113:2011-21.
11. Kawabata S, Oka M, Shiozawa K. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001, 280:1216-23.
12. Jonker JW, Smit JW, Brinkhuis RF. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000, 92:1651-6.
13. Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J. Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci 2005, 96:457-65.
14. Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev 2009, 61:26-33.
15. Kage K, Tsukahara S, Sugiyama T. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer 2002, 97:626-30.
16. Kage K, Fujita T, Sugimoto Y. Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. Cancer Sci 2005, 96:866-72.
17. Rabindran SK, He H, Singh M. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 1998, 58:5850-8.
18. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000, 60:47-50.
19. Sugimoto Y, Tsukahara S, Sato S. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91. J Gene Med 2003, 5:366-76.
20. Sugimoto Y, Aksentijevich I, Gottesman MM, Pastan I. Efficient expression of drug-selectable genes in retroviral vectors under control of an internal ribosome entry site. Biotechnology 1994, 12:694-8.
21. Sugimoto Y, Hrycyna CA, Aksentijevich I, Pastan I, Gottesman MM. Coexpression of a multidrug-resistance gene (MDR1) and herpes simplex virus thymidine kinase gene as part of a bicistronic messenger RNA in a retrovirus vector allows selective killing of MDR1-transduced cells. Clin Cancer Res 1995, 1:447-57.
22. Sugimoto Y, Sato S, Tsukahara S. Coexpression of a multidrug resistance gene (MDR1) and herpes simplex virus thymidine kinase gene in a bicistronic retroviral vector Ha-MDR-IRES-TK allows selective killing of MDR1-transduced human tumors transplanted in nude mice. Cancer Gene Ther 1997, 4:51-8.
23. Henriksen U, Fog JU, Litman T, Gether U. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. J Biol Chem 2005, 280:36926-34.
24. Xu J, Liu Y, Yang Y, Bates S, Zhang JT. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J Biol Chem 2004, 279:19781-9.
25. Xu J, Peng H, Chen Q, Liu Y, Dong Z, Zhang JT. Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity. Cancer Res 2007, 67:4373-81.
26. Choi K, Chen CJ, Kriegler M, Roninson IB. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 1988, 53:519-29.
27. Cardarelli CO, Aksentijevich I, Pastan I, Gottesman MM. Differential Effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res 1995, 55:1086-91.
28. Maliepaard M, Scheffer GL, Faneyte IF. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001, 61:3458-64.
29. Zhou S, Schuetz JD, Bunting KD. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001, 7:1028-34.
30. Jonker JW, Merino G, Musters S. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 2005, 11:127-9.
31. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 2004, 3:1119-25.
32. Burger H, van Tol H, Boersma AW. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004, 104:2940-2.
33. Elkind NB, Szentpetery Z, Apati A. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 2005, 65:1770-7.
34. McDowell HP, Meco D, Riccardi A. Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models. Int J Cancer 2007, 120:1141-9.
35. Shi Z, Peng XX, Kim IW. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007, 67:11012-20.
36. Brendel C, Scharenberg C, Dohse M. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007, 21:1267-75.
37. Polli JW, Humphreys JE, Harmon KA. The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({{[2-(methy-lsulfonyl)ethyl]amino} methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008, 36:695-701.
38. Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib. (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ABC transporters, P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2008, 37:359-65.
39. Dai CL, Liang YJ, Wang YS. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett 2009, 279:74-83.
40. Imai Y, Nakane M, Kage K. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002, 1:611-6.
41. Sparreboom A, Gelderblom H, Marsh S. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther 2004, 76:38-44.
42. Cusatis G, Gregorc V, Li J. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 2006, 98:1739-42.
43. Rudin CM, Liu W, Desai A. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008, 26:1119-27.
44. Yoshioka S, Katayama K, Okawa C. The identification of two germ-line mutations in the human breast cancer resistance protein gene that result in the expression of a low/non-functional protein. Pharm Res 2007, 24:1108-17.
45. Kawahara H, Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Pharmacologicalinteraction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene. Cancer Sci 2010, http://dx.doi.org/10.1111/j.1349-7006.2010.01539.x., DOI: [Epub ahead of print]